



## COLORADO

Prescription Drug  
Affordability Board

Division of Insurance

### **Prescription Drug Affordability Advisory Council DRAFT Minutes**

Thursday, April 24, 2025; 9 - 11 am MT Virtual Meeting

[Meeting Recording](#)

#### **Meeting Attendance**

##### **Present**

Kimberley Jackson  
Gail deVore  
Katelin Lucariello  
Brett McQueen  
Nathan Wilkes  
Marc Reese  
Leah Lindahl  
Bob Mulch  
Ingrid Pan  
Fayez Azeez  
Richard Miranda

##### **Absent**

Sarita Parikh  
Kim Bimestefer

##### **DOI Staff**

Sophie Thomas  
Sagun Sharma  
Callie Shelton  
Kate Davidson  
Moroj Salih

##### **General Counsel from the AGO**

Kyle McDaniel

#### **Agenda**

- Call to Order, Roll Call, Minutes Approval
- Director Updates
- PDAAC Business
  - PDAB Chair Report Out
  - Draft Data Submission Guide (DSG)
  - Discussion on Best Practices for Gathering Stakeholder Information During Affordability Reviews
- Public Comment

#### **Call to Order & Roll Call**

Dr. Kimberley Jackson, PDAAC chair, called the meeting to order at 9:02 am. All Advisory Council members were present, with the exception of Sarita Parikh and Kim Bimestefer.

#### **January 28 Minutes Approval**

Gail DeVore moved, Marc Reece seconded, and PDAAC members voted to approve the January 28 meeting minutes.

[DECISION: PDAAC voted to approve the January 28 minutes at 9:04 am.](#)

**Director Updates and PDAAC Business****PDAB Chair Report Out**

At 9:05 am, PDAB chair, Dr. Gail Mizner provided Board updates to the Advisory Council. Dr. Mizner gave an update on the Amgen case, followed by the cost-benefit analysis and regulatory analysis for Enbrel's upper payment limit (UPL). Dr. Mizner also informed the Advisory Council about the APCD data miscategorization discussed during the Board's April 11th meeting. At the same meeting, the Board also approved updates to PDAB Affordability Review policy. Finally, Dr. Mizner requested the Advisory Council to provide ideas on what policy recommendations the Board should make to the General Assembly in its annual summary report for 2024.

At 9:34 am, Dr. Mizner introduced the new PDAB director, Sophie Thomas, to the Advisory Council.

**Discussion on Best Practices for Gathering Stakeholder Information During Affordability Reviews**

Ms. Thomas presented the update to PDAB Policy No. 4: Affordability Review that states the Board may direct staff to facilitate a workgroup with members of PDAAC, Rare Disease Advisory Council (RDAC), and other stakeholders to identify best practices around gathering patient information during an affordability review. On April 11, the Board directed staff to conduct this workgroup. Dr. Jackson led the PDAAC members through a discussion of the goals of the workgroup, during which members provided their input on each of the goals. Staff presented next steps for the stakeholder workgroup.

**Draft Data Submission Guide (DSG)**

At 10:20 am, staff presented the changes made to the DSG per PDAAC's feedback. Staff informed the Council that the Board will be finalizing and approving the DSG at its May 23 meeting before it is made available to the public.

**Public Comment**

Starting at 10:34 am, the following individuals offered public comment to the Advisory Council:

- Rainier Simons - Community Access National Network (CANN)
- Amanda Boone - Cystic Fibrosis (CF) United
- Bridget Seritt - Advocates for Compassionate Therapy Now
- Vanessa Lathan - Ensuring Access through Collaborative Health (EACH) and Patient Inclusion Council (PIC)
- Candace DeMatteis - Partnership to Fight Chronic Disease

**Adjourn**

Dr. Jackson adjourned the meeting at 10:50 am.



**COLORADO**

**Prescription Drug  
Affordability Board**

Division of Insurance